2023 Guidance and Q3 Earnings

67 potential new vaccines and medicines in pipeline Phase II-27 assets Infectious diseases HIV (ViiV) Respiratory/Immunology Oncology Opportunity driven 3437949 4406371 3536852 3528869 4023393 4178116 5101956 5101955 4106647 4348413 4382276 4396687 3993129 Recombinant protein, adjuvanted* Live, attenuated GMMA* Viral vector with recombinant protein, adjuvanted* Recombinant protein, OMV, conjugated vaccine Live, attenuated MAPS* MAPS* Recombinant protein, adjuvanted* GMMA mRNA* 3036656 sanfetrinem cilexetil (GV118819) BVL-GSK098 VIR-2482 3810109 3739937 4004280 4011499 Benlysta (belimumab) 3858279 1070806 4527226 (AL-101) belrestotug (4428859) 4532990 mRNA* Adjuvanted recombinant subunit Leucyl t-RNA synthetase inhibitor* Serine beta lactamase inhibitor* Ethionamide booster* Neutralizing monoclonal antibody*5 Broadly neutralizing antibody* Maturation inhibitor Capsid protein inhibitor Capsid protein inhibitor Anti-BLys antibody Anti-CCL17 antibody* Anti-IL18 antibody Anti-sortilin antibody* Anti-TIGIT antibody* HSD17B13 siRNA* GSK Malaria fractional dose MMRV new strain Shigella Therapeutic hepatitis B virus¹** MenABCWY, 2nd Gen¹ Varicella new strain Adult pneumococcal disease, 24-valent Paediatric pneumococcal disease, 24-valent Human papillomavirus Gonorrhoea¹ Seasonal flu COVID-19 Cytomegalovirus¹ Tuberculosis Tuberculosis Tuberculosis Influenza HIV HIV6 HIV6 HIV6 Systemic sclerosis associated interstitial lung disease Osteoarthritis pain** Atopic dermatitis Alzheimer's disease Non-small cell lung cancer** Non-alcoholic steatohepatitis *In-licence or other alliance relationship with third party **Additional indications or candidates also under investigation In registration 1. In phase I/II study 2. Transition activities underway to enable further progression by partner 3. Phase I study start imminent 4. GSK has an exclusive global license option to co-develop and commercialise the candidate 5. GSK has exclusive option to co-develop post phase II 6. Phase II study start imminent 7. Phase III study start expected in 2023 8. Phase III trial in patients with progranulin gene mutation 9. Approved in US 37 337

View entire presentation